NCT03670901View on ClinicalTrials.gov

A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)

PHASE3TerminatedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

November 13, 2018

Primary Completion Date

March 7, 2019

Study Completion Date

March 7, 2019

Conditions

Diffuse Large B-Cell Lymphoma

Interventions

BIOLOGICAL

JHL1101

JHL1101, 100mg/10mL

BIOLOGICAL

MabThera

Rituximab, 100mg/10mL

Trial Locations (1)

100142

Beijing Cancer Hospital, Beijing

Sponsors

Lead Sponsor

JHL Biotech, Inc.

All Listed Sponsors

lead

JHL Biotech, Inc.

INDUSTRY